As published in a research note from H.C. Wainwright on June 08, 2020, Protalix BioTherapeutics Inc [PLX] has been retained to a Buy and the price target has been revised to $11. Analysts at Rodman & Renshaw resumed the stock at ‘”a Buy”‘ outlook in a report released in mid April. As of April 04, 2016, Rodman & Renshaw has initiated its “Buy” rating for PLX. Earlier on April 23, 2015, Jefferies upgraded its rating. Their new recommendation was “a Buy” for PLX stock which previously was a “a Hold”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analyzing PLX Stock Performance
During the last five days, there has been a surge of approximately 21.55%. Over the course of the year, Protalix BioTherapeutics Inc shares have dropped approximately -20.79%. Shares of the company reached a 52-week high of $1.8500 on 01/03/24 and a 52-week low of $0.8214 on 08/14/24. A 50-day SMA is recorded $1.1054, while a 200-day SMA reached $1.1811. Nevertheless, trading volume fell to 1.45 million shares from 0.3 million shares the previous day.
Support And Resistance Levels for Protalix BioTherapeutics Inc (PLX)
According to the 24-hour chart, there is a support level at 1.3100, which, if violated, would cause prices to drop to 1.2100. In the upper region, resistance lies at 1.4600. The next price resistance is at 1.5100. RSI (Relative Strength Index) is 68.13 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0962, which suggests the price will decrease in the coming days. Percent R is at 0.00%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
Which companies own the most shares of Protalix BioTherapeutics Inc (PLX)?
On November 12, 2014, R. F. Lafferty assigned a price target of “a Buy” to the stock and reiterated coverage with a $5.
